Trial Profile
A Single Center, Randomized, Double-Masked, Placebo Controlled Study Evaluating the Safety and Efficacy of 0.25% PG101 and 1.0% PG101 in Subjects With Dry Eye Syndrome
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 03 Feb 2016
Price :
$35
*
At a glance
- Drugs PG 101 (Primary)
- Indications Dry eyes
- Focus Therapeutic Use
- Sponsors Rhodes Pharmaceuticals
- 03 Feb 2016 New trial record